Blogs

Biotech and the Election: This election will be the food movement’s moment of truth, says Michael Pollan

Biotechnology was supposed to trigger a food revolution: Higher crop yields and the end of world hunger

"This election will be the food movement’s moment of truth, says Michael Pollan" 

 

Biotechnology was supposed to trigger a food revolution: Higher crop yields and the end of world hunger. Or so promised once-chemical producer Monsanto, now the mother of all agricultural biotechnology companies. But 20 years on, conventional methods of breeding have actually done more to lift crop yield than genetically modified crops ever have, says food journalist, author, and professor Michael Pollan.

Durata Therapeutics In.c to Move to CT, 80 New Jobs Created

Governor Dannel P. Malloy today announced the state will provide up to $2.25 million in grants to Durata Therapeutics

Governor Dannel P. Malloy today announced the state will provide up to $2.25 million in grants to Durata Therapeutics, Inc. to support the relocation of its research and development, clinical, and regulatory operations from New Jersey to Branford. The company, whose headquarters are in Chicago, Illinois, will create up to 80 new, full-time jobs in Connecticut. “The goal of Bioscience Connecticut is twofold – creating good paying jobs with good benefits for residents in an industry that is poised for growth,” said Governor Malloy.

Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy

Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients

Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients with untreated castration-resistant prostate cancer (CRPC), results of a large international trial showed. Men randomized to a regimen of lenalidomide, docetaxel, and prednisone, had a 53% increased mortality hazard, a 32% greater hazard for progression, and significantly higher rates of neutropenia, febrile neutropenia, and multiple non-hematologic adverse events.

Heart Drug Eases Pain of Rare Disease

An older medication originally approved to treat heart problems eases pain and stiffness from a very rare muscle disease

An older medication originally approved to treat heart problems eases pain and stiffness from a very rare muscle disease, a new study reports. The findings are good news not only for the relatively small number of people around the world estimated to have the disease—nondystrophic myotonia—but also for many other patients who have one of the thousands of other diseases that are very rare, neurologists say.

Pages